IO Biotech, Inc. (the “Company”) is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company’s T-win platform is designed to activate naturally occurring T-cells to target immunosuppressive mechanisms. The Company’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as Indoleamine 2,3-dehydrogenase (IDO) and programmed death ligand (PD-L1).